Human chorionic gonadotropin

Effects and efficacy:
Injectable choriotropin can be used for: diagnosis and treatment of prepubertal cryptorchidism. Male infertility caused by hypopituitarism can be used in combination with urinary gonadotropin. Those with long-term hypogonadotropin should also be treated with testosterone. Female anovulatory infertility caused by pituitary gonadotropin deficiency is often treated with clomiphene after ineffective treatment. Injectable choriotropin and urinary gonadotropin are often used in combination to promote ovulation. For in vitro fertilization to obtain multiple oocytes, it needs to be used in combination with urinary gonadotropin. Treatment of female corpus luteum insufficiency. Functional uterine bleeding, threatened abortion in early pregnancy, habitual abortion.
Usage and dosage:
Adult dosage for male hypogonadism caused by insufficient gonadotropin function, intramuscular injection of 1000-4000 units, 2-3 times a week, for several weeks to several months. To promote spermatogenesis, treatment needs to last for 6 months or longer. If the sperm count is less than 5 million/ml, urinary gonadotropin should be used in combination for about 12 months. For ovulation induction, for female anovulatory infertility or in vitro fertilization, 5000-10000 units are injected intramuscularly one day after the last dose of urinary gonadotropin or 5-7 days after the last dose of clomiphene. Continuous treatment for 3-6 cycles, if no effect, stop the drug. For luteal insufficiency, 1500 units are injected every other day from the date of ovulation on the 15th to 17th day of the menstrual period, and used for 5 times in a row. Adjustments can be made according to the patient’s response. After pregnancy, the original dose must be maintained until 7-10 weeks of pregnancy. For functional uterine bleeding, 1000-3000 units are injected intramuscularly. For habitual abortion and threatened abortion, 1000-5000 units are injected intramuscularly. For pediatric dosage, testicular function test for developmentally retarded patients, 2000 units are injected intramuscularly once a day for 3 consecutive days. For prepubertal cryptorchidism, intramuscular injection of 1000-5000 units, 2-3 times a week, discontinue use after a good effect is achieved. The total number of injections should not exceed 10 times.
Adverse reactions:
When used to promote ovulation, the most common symptoms are ovarian cysts or mild to moderate ovarian enlargement, accompanied by mild bloating, stomach pain, and pelvic pain, which generally subside within 2 to 3 weeks. Rarely, severe ovarian hyperstimulation syndrome is caused by the rapid accumulation of fluid in the chest, abdominal and pericardial cavities due to the significant increase in vascular permeability, which causes a variety of complications, such as decreased blood volume, electrolyte imbalance, hemoconcentration, abdominal hemorrhage, thrombosis, etc. Clinical manifestations include severe pain in the abdomen or pelvis, indigestion, edema, decreased urine volume, nausea, vomiting, or diarrhea, shortness of breath, lower limb swelling, etc. It often occurs 7 to 10 days after ovulation or after the end of treatment. Severe reactions can be life-threatening. When used to treat cryptorchidism, male precocious puberty may occasionally occur, manifested as acne, penis and testicle enlargement, increased pubic hair growth, and rapid height growth. Less common adverse reactions include: breast enlargement, headache, irritability, depression, and fatigue. Occasionally, there is local pain and allergic rash after injection. Using injectable chorionic gonadotropin to promote ovulation may increase the rate of multiple births or premature births of newborns.
Drug contraindications:
Allergic to this product is contraindicated. Use with caution in case of renal impairment. Use with caution during pregnancy and lactation.